Literature DB >> 8478023

Theiler's murine encephalomyelitis virus induces tumour necrosis factor-alpha in murine astrocyte cell cultures.

A Sierra1, N Rubio.   

Abstract

Cytokines have been postulated to exert an important modulatory and recruiting role in demyelination induced by Theiler's murine encephalomyelitis virus (TMEV) in SJL/J mice. Using a cytolytic bioassay and ELISA, we have detected and quantified a cytokine, tumour necrosis factor-alpha (TNF-alpha), in supernatants from astrocyte cultures infected in vitro with TMEV. TNF was detected only after TMEV-specific infection of astrocyte cultures (approximately 200-400 U/ml). In vitro TNF synthesis appeared in a dose- and time-dependent manner and was produced by both SJL/J (a strain susceptible to TMEV-induced demyelination) and BALB/c (a resistant strain) astrocytes. The precise nature of TNF activity was further assessed by fast protein liquid chromatography (FPLC) and antibody neutralization. These results indicate an active role for astrocytes as accessory immune cells in our experimental model for multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478023      PMCID: PMC1421825     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Variations in genetic control of susceptibility to Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. I. Differences between susceptible SJL/J and resistant BALB/c strains map near the T cell beta-chain constant gene on chromosome 6.

Authors:  R W Melvold; D M Jokinen; R L Knobler; H L Lipton
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

2.  Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation.

Authors:  W Fierz; B Endler; K Reske; H Wekerle; A Fontana
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes.

Authors:  D S Robbins; Y Shirazi; B E Drysdale; A Lieberman; H S Shin; M L Shin
Journal:  J Immunol       Date:  1987-10-15       Impact factor: 5.422

Review 4.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  A Friedmann; Y Lorch
Journal:  Prog Med Virol       Date:  1985

5.  Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs.

Authors:  R J Clatch; H L Lipton; S D Miller
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

6.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro.

Authors:  K W Selmaj; C S Raine
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

7.  Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens).

Authors:  M Rodriguez; W P Lafuse; J Leibowitz; C S David
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

8.  Astrocytes of the brain synthesize interleukin 3-like factors.

Authors:  K Frei; S Bodmer; C Schwerdel; A Fontana
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

9.  Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells.

Authors:  B Tedeschi; J N Barrett; R W Keane
Journal:  J Cell Biol       Date:  1986-06       Impact factor: 10.539

10.  Tumor necrosis factor induces expression of MHC class I antigens on mouse astrocytes.

Authors:  E Lavi; A Suzumura; D M Murasko; E M Murray; D H Silberberg; S R Weiss
Journal:  J Neuroimmunol       Date:  1988-06       Impact factor: 3.478

View more
  8 in total

1.  Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease.

Authors:  JoAnn P Palma; Daeho Kwon; Neil A Clipstone; Byung S Kim
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  An in vitro experimental model of neuroinflammation: the induction of interleukin-6 in murine astrocytes infected with Theiler's murine encephalomyelitis virus, and its inhibition by oestrogenic receptor modulators.

Authors:  Nazario Rubio; Marie Cerciat; Mikko Unkila; Luis M Garcia-Segura; Maria-Angeles Arevalo
Journal:  Immunology       Date:  2011-05-13       Impact factor: 7.397

3.  Survivin prevents apoptosis by binding to caspase-3 in astrocytes infected with the BeAn strain of Theiler's murine encephalomyelitis virus.

Authors:  Nazario Rubio; Luis Miguel Garcia-Segura; Maria-Angeles Arevalo
Journal:  J Neurovirol       Date:  2012-05-26       Impact factor: 2.643

Review 4.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

5.  Demonstration of the presence of an interleukin-1 receptor on the surface of murine astrocytes and its regulation by cytokines and Theiler's virus.

Authors:  N Rubio
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

Review 6.  Immunology of Theiler's murine encephalomyelitis virus infection.

Authors:  E L Oleszak; J Kuzmak; R A Good; C D Platsoucas
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

7.  Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens.

Authors:  C Torres; I Aránguez; N Rubio
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

8.  High-neurovirulence GDVII virus induces apoptosis in murine astrocytes through tumor necrosis factor (TNF)-receptor and TNF-related apoptosis-inducing ligand.

Authors:  Nazario Rubio; Begoña Martin-Clemente; Howard L Lipton
Journal:  Virology       Date:  2003-07-05       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.